Update on epidemiological aspects of progressive supranuclear palsy
暂无分享,去创建一个
[1] S. Ohta,et al. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate , 1996, Neuroscience Letters.
[2] M. Hallett,et al. Research goals in progressive supranuclear palsy , 2000, Movement disorders : official journal of the Movement Disorder Society.
[3] S. Ohta,et al. A Novel and Neurotoxic Tetrahydroisoquinoline Derivative In Vivo: Formation of 1,3‐Dimethyl‐1,2,3,4‐Tetrahydroisoquinoline, a Condensation Product of Amphetamines, in Brains of Rats Under Chronic Ethanol Treatment , 1990, Journal of neurochemistry.
[4] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[5] I Litvan,et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[6] W. Kamphorst,et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations , 1999, Annals of neurology.
[7] R. Marconi,et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy , 2000, Neurology.
[8] B. Hyman,et al. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. , 1999, Journal of neuropathology and experimental neurology.
[9] L. Golbe. Progressive supranuclear palsy in the molecular age , 2000, The Lancet.
[10] J. Jankovic,et al. Progressive supranuclear palsy and a multi‐infarct state , 1987, Neurology.
[11] J. Kril,et al. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. , 2000, Archives of neurology.
[12] R. Cody,et al. Follow-up study of risk factors in progressive supranuclear palsy , 1996, Neurology.
[13] E. Neafsey,et al. Indole‐N‐Methylation of β‐Carbolines: The Brain's Bioactivation Route to Toxins in Parkinson's Disease? a, b , 1992, Annals of the New York Academy of Sciences.
[14] T. Niwa,et al. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. , 1989, Journal of chromatography.
[15] A. Lees,et al. The clinical features and natural history of the Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1986, Neurology.
[16] F. Mastaglia,et al. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases. , 1973, Proceedings of the Australian Association of Neurologists.
[17] E. Mccrank. PSP risk factors , 1990, Neurology.
[18] L. Golbe,et al. Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.
[19] K. Kikuchi,et al. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[20] E. Beghi,et al. Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis , 2001, Neurology.
[21] M. Friedrich. Pesticide study aids Parkinson research. , 1999, JAMA.
[22] W. Kuhn,et al. Elevated levels of harman and norharman in cerebrospinal fluid of Parkinsonian patients , 2005, Journal of Neural Transmission.
[23] I Litvan,et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[24] E. Mendez-Alvarez,et al. Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-β-carboline by cigarette smoke , 2001, Neuroscience Letters.
[25] C. Mariani,et al. n-Hexane induces Parkinsonism in rodents , 1990, Brain Research.
[26] K. Rabheru,et al. Four Cases of Progressive Supranuclear Palsy in Patients Exposed to Organic Solvents* , 1989, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[27] Posttraumatic akinetic‐rigid syndrome resembling Parkinson's disease: A report on three patients , 2000, Movement disorders : official journal of the Movement Disorder Society.
[28] G. Schellenberg,et al. A distinct familial presenile dementia with a novel missense mutation in the tau gene. , 1999, Neuroreport.
[29] C. Goetz,et al. Trauma and movement disorders. , 1992, Neurologic clinics.
[30] M N Rossor,et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype , 2001, Neurology.
[31] T. Nagatsu,et al. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.
[32] D. Dickson,et al. Microglial Activation Parallels System Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 2001, Journal of neuropathology and experimental neurology.
[33] J. Olszewski,et al. Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .
[34] I Litvan,et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.
[35] J. Rogers,et al. Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease , 1992, Neurology.
[36] S. Croul,et al. TGF-β receptors-I and -II immunoexpression in Alzheimer’s disease: a comparison with aging and progressive supranuclear palsy , 1998, Neurobiology of Aging.
[37] E. Neafsey,et al. Dopamine uptake inhibitory capacities of β-carboline and 3,4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products , 1990, Brain Research.
[38] L. Thal,et al. Clinical trials in Alzheimer disease: debate on the use of placebo controls. , 1999, Alzheimer disease and associated disorders.
[39] T. Révész,et al. Neuronal cytoskeletal changes are an early consequence of repetitive head injury , 1999, Acta Neuropathologica.
[40] Jean-François Dartigues,et al. Education and Risk for Alzheimer's Disease: Sex Makes a Difference EURODEM Pooled Analyses , 2000 .
[41] I. Litvan,et al. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy , 2001, Neurology.
[42] M. Tabaton,et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy , 2000, Annals of neurology.
[43] M G Spillantini,et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. , 1999, Journal of neuropathology and experimental neurology.
[44] A. Rajput,et al. Progressive Supranuclear Palsy , 2001, Drugs & aging.
[45] S. Ohta,et al. Novel Endogenous 1,2,3,4‐Tetrahydroisoquinoline Derivatives: Uptake by Dopamine Transporter and Activity to Induce Parkinsonism , 1998, Journal of neurochemistry.
[46] G. Schellenberg,et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) , 1999, Brain : a journal of neurology.
[47] I Litvan,et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.
[48] N. Mantel,et al. Geographic patterns of parkinsonism-dementia complex on Guam. 1956 through 1985. , 1990, Archives of neurology.
[49] T. Niwa,et al. Detection of tetrahydroisoquinoline in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. , 1989, Journal of chromatography.
[50] S. Ohta,et al. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to Parkinson's disease. , 1988, Life sciences.
[51] K. Flanders,et al. Transforming Growth Factor-β: Neuronal and Glial Expression in CNS Degenerative Diseases , 1995 .
[52] I Litvan,et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias , 1999, Neurology.
[53] N. Mantel,et al. Patterns of acquiring parkinsonism-dementia complex on Guam. 1944 through 1985. , 1990, Archives of neurology.
[54] M. Goedert,et al. Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.
[55] M. Nefzger,et al. A retrospective study of smoking in Parkinson's disease. , 1968, American journal of epidemiology.
[56] C. DeCarli,et al. Head injury and the risk of AD in the MIRAGE study , 2000, Neurology.
[57] C. Tanner,et al. Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.
[58] I Litvan,et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.
[59] Y. Lapierre. Pharmacological therapy of dysthymia , 1994, Acta psychiatrica Scandinavica. Supplementum.
[60] G. Schellenberg,et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.
[61] M. Pericak-Vance,et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease , 1996, The Lancet.
[62] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[63] T. Niwa,et al. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. , 1988, Journal of chromatography.
[64] D. Maraganore,et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 , 1997, Neurology.
[65] E. Neafsey,et al. Differential Cytotoxicities of N‐Methyl‐β‐Carbolinium Analogues of MPP+ in PC12 Cells: Insights into Potential Neurotoxicants in Parkinson's Disease , 1994, Journal of neurochemistry.
[66] J. Bogousslavsky,et al. Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. , 1997, Archives of neurology.
[67] P. Laippala,et al. Head injuries and cognitive decline among older adults , 1999, Neurology.
[68] K. Hirayama,et al. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy , 1994, Acta neurologica Scandinavica.
[69] I Litvan,et al. Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.
[70] A. Hofman,et al. Rates and risk factors for dementia and Alzheimer’s disease , 1999, Neurology.
[71] M. Diamond,et al. Enriching Heredity: The Impact of the Environment on the Anatomy of the Brain , 1988 .
[72] S. Ohta,et al. 1‐Methyl‐ 1,2,3,4‐Tetrahydroisoquinoline, Decreasing in 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Treated Mouse, Prevents Parkinsonism‐Like Behavior Abnormalities , 1991, Journal of neurochemistry.
[73] G. Schellenberg,et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. , 1997, American journal of epidemiology.
[74] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[75] Y Ben-Shlomo,et al. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.
[76] E. Kokmen,et al. Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. , 1999, American journal of epidemiology.
[77] A. Ludolph,et al. Slow toxins, biologic markers, and long‐latency neurodegenerative disease in the western Pacific region , 1991, Neurology.
[78] G. Pezzoli,et al. PARKINSONISM DUE TO n-HEXANE EXPOSURE , 1989, The Lancet.
[79] D. Maraganore,et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[80] I Litvan,et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination , 1998, Journal of neurology, neurosurgery, and psychiatry.
[81] J. Silverman,et al. A case‐control study of Alzheimer's disease in China , 1992, Neurology.
[82] A. Delacourte,et al. Neurofibrillary Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 1999, Journal of neurochemistry.
[83] E. Neafsey,et al. Striatal dopaminergic toxicity following intranigral injection in rats of 2-methyl-norharman, a β-carbolinium analog of N-methyl-4-phenylpyridinium ion (MPP+) , 1989, Neuroscience Letters.
[84] D. Maraganore,et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.
[85] J. Troncoso,et al. Overexpression of four‐repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease , 1999, Annals of neurology.
[86] S. Ohta,et al. Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter. , 1998, European journal of pharmacology.
[87] J. Langston,et al. Parkinsonism caused by petroleum waste ingestion , 1994, Neurology.
[88] J. Jankovic,et al. Vascular progressive supranuclear palsy. , 1994, Journal of neural transmission. Supplementum.
[89] Alexis Elbaz,et al. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study , 1999, The Lancet.
[90] G. Schellenberg,et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[91] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[92] S. Ohta,et al. 1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.
[93] J. Dambrosia,et al. Environmental— occupational risk factors and familial associations in multiple system atrophy: A preliminary investigation , 1991, Clinical Autonomic Research.
[94] L. Golbe,et al. Risk factors for progressive supranuclear palsy , 1988, Neurology.
[95] K. Beyreuther,et al. Bcl‐xl‐Specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states , 1997, Journal of neuroscience research.
[96] P. Satz. Brain reserve capacity on symptom onset after brain injury: A formulation and review of evidence for threshold theory. , 1993 .
[97] Claire Shepherd,et al. Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms , 2000, Clinical and experimental pharmacology & physiology.
[98] E. Neafsey,et al. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. , 1990, Brain research.
[99] C. Colosimo,et al. Presymptomatic Hypertension in Progressive Supranuclear Palsy , 1998 .
[100] T. Niwa,et al. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.
[101] I. Mackenzie,et al. Positive CSF HSV PCR in patients with GBM: A note of caution , 2000, Neurology.
[102] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[103] D. Burn,et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. , 2001, Brain : a journal of neurology.
[104] A. Hofman,et al. Head trauma and risk of dementia and Alzheimer’s disease , 1999, Neurology.
[105] J. P. Brandel,et al. Accuracy of the Clinical Diagnosis of Corticobasal Degeneration , 1997, Neurology.